J S Currier

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint The safety of antiretroviral drugs
    Christopher N Tymchuk
    Expert Opin Drug Saf 7:1-4. 2008
  2. pmc Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Lipids Health Dis 12:23. 2013
  3. ncbi request reprint Coronary heart disease in HIV-infected individuals
    Judith S Currier
    David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California 90095, USA
    J Acquir Immune Defic Syndr 33:506-12. 2003
  4. ncbi request reprint Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults
    Judith S Currier
    Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    AIDS 21:1137-45. 2007
  5. ncbi request reprint Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study
    Judith Currier
    UCLA Center for Care, Los Angeles, CA, United States
    Antivir Ther 13:297-306. 2008
  6. pmc Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial
    Judith Currier
    University of California, Los Angeles, CA, USA
    Ann Intern Med 153:349-57. 2010
  7. ncbi request reprint Management of metabolic complications of therapy
    Judith Currier
    University of California Los Angeles, Department of Medicine, Division of Infectious Diseases, 37 121 CHS, Los Angeles CA 90095, USA
    AIDS 16:S171-6. 2002
  8. pmc Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men
    Obi C Umeh
    David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Clin Pharmacol 51:1665-73. 2011
  9. ncbi request reprint Cardiovascular risk associated with HIV therapy
    Judith S Currier
    Center for AIDS Research and Education, University of California, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 31:S16-23; discussion S24-5. 2002
  10. pmc Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks
    Judith S Currier
    University of California, Los Angeles, School of Medicine, Department of Medicine, USA
    AIDS Patient Care STDS 25:333-40. 2011

Research Grants

Detail Information

Publications65

  1. ncbi request reprint The safety of antiretroviral drugs
    Christopher N Tymchuk
    Expert Opin Drug Saf 7:1-4. 2008
    ..However, it is crucial that vigilance be maintained in monitoring for side effects, particularly in resource-limited settings...
  2. pmc Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Lipids Health Dis 12:23. 2013
    ..Dysfunctional HDL has increased redox activity and reduced antioxidant properties, but it is unknown whether abnormal HDL function is associated with progression of atherosclerosis in HIV-1-infected subjects...
  3. ncbi request reprint Coronary heart disease in HIV-infected individuals
    Judith S Currier
    David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California 90095, USA
    J Acquir Immune Defic Syndr 33:506-12. 2003
    ..CHD incidence appears accelerated among young HIV-infected individuals. Strategies to reduce CHD risk should be incorporated into HIV primary care...
  4. ncbi request reprint Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults
    Judith S Currier
    Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    AIDS 21:1137-45. 2007
    ..To compare the rate of change in intima-media thickness (IMT) of the carotid artery among uninfected subjects and HIV-infected subjects receiving or not receiving protease inhibitor (PI) regimens over a 144 week period...
  5. ncbi request reprint Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study
    Judith Currier
    UCLA Center for Care, Los Angeles, CA, United States
    Antivir Ther 13:297-306. 2008
    ..This Phase IIb study explored the antiviral activity and safety of the investigational CCR5 antagonist aplaviroc (APL) in antiretroviral-naive patients harbouring R5-tropic virus...
  6. pmc Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial
    Judith Currier
    University of California, Los Angeles, CA, USA
    Ann Intern Med 153:349-57. 2010
    ..Women account for an increasing proportion of patients with HIV-1 but remain underrepresented in antiretroviral clinical trials...
  7. ncbi request reprint Management of metabolic complications of therapy
    Judith Currier
    University of California Los Angeles, Department of Medicine, Division of Infectious Diseases, 37 121 CHS, Los Angeles CA 90095, USA
    AIDS 16:S171-6. 2002
    ..While these efforts must continue it is hoped that a new focus on prevention of metabolic complications will begin to emerge in the year ahead...
  8. pmc Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men
    Obi C Umeh
    David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Clin Pharmacol 51:1665-73. 2011
    ..Women had higher RTV AUC(0-12 h) and lower CL/F with both formulations. The mechanism of the sex difference in RTV CL/F warrants elucidation...
  9. ncbi request reprint Cardiovascular risk associated with HIV therapy
    Judith S Currier
    Center for AIDS Research and Education, University of California, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 31:S16-23; discussion S24-5. 2002
  10. pmc Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks
    Judith S Currier
    University of California, Los Angeles, School of Medicine, Department of Medicine, USA
    AIDS Patient Care STDS 25:333-40. 2011
    ..317). DRV/r-based therapy was associated with small to moderate changes in metabolic parameters, and few between-gender differences were observed. Levels of self-reported, body-related distress improved for women and men over 48 weeks...
  11. pmc Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure
    Judith S Currier
    Center for Clinical AIDS Research and Education, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA
    AIDS 19:927-33. 2005
    ..The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood...
  12. ncbi request reprint Discontinuing prophylaxis for opportunistic infection: guiding principles
    J S Currier
    Department of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Infect Dis 30:S66-71. 2000
    ..This article reviews current data on predicting risk of opportunistic infection, the most critical of these factors...
  13. ncbi request reprint Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease
    J S Currier
    Center for AIDS Research and Education, University of California Los Angeles, Los Angeles, CA 90095, USA
    Clin Infect Dis 32:1615-22. 2001
    ..This study documents that bacterial infections are common among patients with advanced HIV disease, especially among women...
  14. ncbi request reprint Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team
    J S Currier
    University of California, Los Angeles, CARE Center, 10833 LeConte Avenue, Room BH 412 CHS, Los Angeles, CA 90095, USA
    Ann Intern Med 133:493-503. 2000
    ..Patients infected with HIV who experience increases in CD4(+) cell counts are at reduced risk for opportunistic infections. However, the safety of discontinuing prophylaxis against Mycobacterium avium complex has been uncertain...
  15. ncbi request reprint Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team
    J S Currier
    University of California Los Angeles, Los Angeles, California Harvard School of Public Health, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 24:316-24. 2000
    ..To prospectively examine differences in baseline characteristics and study outcomes between HIV-infected women and men during a clinical trial of nucleoside analogue therapy...
  16. ncbi request reprint Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
    R L Murphy
    Division of Infectious Diseases, Northwestern University Medical School, Illinois, Chicago, IL 60611, USA
    J Infect Dis 179:808-16. 1999
    ..04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy...
  17. ncbi request reprint The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    J J Eron
    Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 181:1622-8. 2000
    ..Persistent replication of HIV in the genital tract may have implications for the selection of resistant virus and sexual transmission of HIV-1...
  18. ncbi request reprint Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections
    P L Williams
    Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
    AIDS 13:1035-44. 1999
    ..To evaluate the predictive value of baseline plasma HIV-1 RNA levels and CD4 lymphocyte counts and early changes in these markers after initiating antiretroviral therapy on the risk of development of specific opportunistic infections (OIs)...
  19. pmc Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection
    C F von Reyn
    Infectious Disease Section, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Diagn Lab Immunol 8:1277-8. 2001
    ..Among 139 subjects, 13% had positive skin test results and 32% had positive LPA results. The LPA may be a more sensitive indicator of prior M. avium infection in this population...
  20. pmc Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study
    Carl Grunfeld
    Medical Service, Department of Veterans Affairs Medical Center, University of California, San Francisco, California 94121, USA
    AIDS 23:1841-9. 2009
    ..However, it is controversial whether HIV infection contributes to accelerated atherosclerosis independent of traditional CVD risk factors...
  21. pmc Antiretroviral therapies in women after single-dose nevirapine exposure
    Shahin Lockman
    Brigham and Women s Hospital, Boston, MA, USA
    N Engl J Med 363:1499-509. 2010
    ..Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus...
  22. ncbi request reprint Predictive markers of HIV-related weight loss and determination of differences between populations with weight loss stratified by opportunistic processes
    R A Zackin
    Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Acquir Immune Defic Syndr 22:189-93. 1999
    ..To describe factors predictive of >10% weight loss among enrolled participants in clinical trials of the AIDS Clinical Trial Group (ACTG)...
  23. doi request reprint Calcification of the internal elastic lamina of coronary arteries
    Robert G Micheletti
    Department of Medicine, Division of Infectious Diseases, University of California at Los Angeles, Los Angeles, CA 90035, USA
    Mod Pathol 21:1019-28. 2008
    ..Internal elastic lamina calcification may result from premature aging due to HIV disease and chronic illness or from metabolic disorders in HIV+ patients...
  24. pmc Atherosclerotic oxalosis in coronary arteries
    Gregory A Fishbein
    Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Cardiovasc Pathol 17:117-23. 2008
    ..In these cases, calcium oxalate deposits have been reported in numerous tissues, including the media of arteries. In any category, calcium oxalate deposition has not been described within atherosclerotic plaques in any arteries...
  25. ncbi request reprint Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women
    Risa M Hoffman
    Division of Infectious Diseases and Center for Clinical AIDS Research Education, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    HIV Clin Trials 8:371-80. 2007
    ..This article analyzes three pivotal trials of the protease inhibitor (PI) fosamprenavir (FPV) with a view to providing a better understanding of potential sex differences in efficacy and safety...
  26. doi request reprint Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider
    Elizabeth R Volkmann
    University of California, Los Angeles, California, USA
    HIV Clin Trials 10:104-9. 2009
    ..To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate...
  27. ncbi request reprint Sex differences in pharmacokinetics and toxicity of antiretroviral therapy
    Obiamiwe C Umeh
    David Geffen School of Medicine at UCLA, Center for Clinical AIDS Research and Education, 9911 W Pico Blvd, Suite 980, Los Angeles, CA 90035, USA
    Expert Opin Drug Metab Toxicol 2:273-83. 2006
    ..These include, but are not limited to, differences in natural history, efficacy and safety of drug treatment. This chapter reviews current data on gender differences in antiretroviral pharmacokinetics and toxicity...
  28. ncbi request reprint Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients
    Obiamiwe C Umeh
    Center for AIDS Research and Education, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr HIV/AIDS Rep 2:132-9. 2005
    ..This article reviews the current literature on HIV-associated dyslipidemias and the metabolic syndrome, their potential effect on future coronary heart disease, and reviews strategies for management...
  29. pmc HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL
    Theodoros Kelesidis
    Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Lipids Health Dis 10:35. 2011
    ..We hypothesized that HIV-1-infected persons on antiretroviral therapy would have pro-inflammatory high density lipoprotein (HDL), and that an apoA-1 mimetic peptide might reverse the inflammatory properties of HDL in these persons...
  30. doi request reprint Mönckeberg sclerosis revisited: a clarification of the histologic definition of Mönckeberg sclerosis
    Robert G Micheletti
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, USA
    Arch Pathol Lab Med 132:43-7. 2008
    ..Since vascular calcification is of great interest to investigators and clinicians, defined criteria for classifying calcified arterial lesions are important...
  31. ncbi request reprint Management of antiretroviral treatment-related complications
    Risa M Hoffman
    UCLA Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA
    Infect Dis Clin North Am 21:103-32, ix. 2007
    ..Fluency in options for preventing and managing complications can provide maximal opportunity to balance treatment effects with quality of life...
  32. pmc Availability of HIV postexposure prophylaxis services in Los Angeles County
    Raphael J Landovitz
    University of California, Los Angeles, Center for Clinical AIDS Research and Education, David Geffen School of Medicine, Los Angeles, CA 90035, USA
    Clin Infect Dis 48:1624-7. 2009
    ..5%) offer postexposure prophylaxis. Ten sites (8.5%) offer postexposure prophylaxis to patients who are uninsured. General availability of postexposure prophylaxis should be a public health priority...
  33. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 13:16-23. 2005
    ....
  34. pmc Complications of HIV disease and antiretroviral treatment
    Anne F Luetkemeyer
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 18:57-65. 2010
    ..This year's conference also highlighted important data on prevention and optimal treatment of common coinfections that occur in HIV-infected individuals, including tuberculosis, influenza, and viral hepatitis...
  35. doi request reprint Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study
    Robert G Micheletti
    University of California, Los Angeles, Los Angeles, CA, USA
    Cardiovasc Pathol 18:28-36. 2009
    ..Studies suggest human immunodeficiency virus-positive (HIV+) patients have an increased risk of coronary artery disease (CAD), yet little is known about the histopathology, severity, or distribution of lesions...
  36. pmc Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis
    Debika Bhattacharya
    University of California, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 55:170-5. 2010
    ..In HIV/ hepatitis C virus (HCV) coinfection, adverse events (AEs) during HCV therapy account for 12%-39% of treatment discontinuations. It is unknown whether sex influences complications...
  37. ncbi request reprint Update on cardiovascular complications in HIV infection
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 17:98-103. 2009
    ..Currier, MD, at an International AIDS Society-USA continuing medical education course in Los Angeles in February 2009. The original presentation is available as a Webcast at www.iasusa.org...
  38. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 17:57-67. 2009
    ..Major areas in which new information was presented are highlighted in this article...
  39. ncbi request reprint Complications of HIV infection and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 11:86-91. 2003
  40. ncbi request reprint A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team
    Judith A Aberg
    Department of Medicine, Division of Infectious Disease, University of California San Francisco, San Francisco, CA, USA
    J Infect Dis 187:1046-52. 2003
    ..44/100 person-years (95% confidence interval, 0.04-8.01). Withdrawal of anti-MAC therapy appears to be safe in patients who have been treated with a macrolide-based regimen for at least 1 year and have an immunologic response on HAART...
  41. pmc Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 48:642-9. 2009
    ....
  42. ncbi request reprint Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 12:31-45. 2004
    ..This article summarizes these presentations...
  43. ncbi request reprint Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Complications of HIV disease and therapy
    Judith S Currier
    University of California Los Angeles and UCLA Center for Clinical AIDS Research and Education, Los Angeles, CA, USA
    Top HIV Med 16:23-30. 2008
    ..As in past years, there was an increase in studies focused on problems predominantly occurring in resource-limited settings...
  44. ncbi request reprint Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy
    Susan L Koletar
    Division of Infectious Diseases, Ohio State University, Columbus, OH 43210, USA
    Clin Infect Dis 39:1500-6. 2004
    ..Descriptions of the durability and consequences of immune reconstitution in patients who start highly active antiretroviral therapy (HAART) while severely immunosuppressed are limited...
  45. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, CA, USA
    Top HIV Med 14:27-35. 2006
    ..This review will summarize information on complications of antiretroviral therapy in resource-limited settings, hepatitis C virus, tuberculosis, and discussion of metabolic, cardiovascular, and renal complications...
  46. ncbi request reprint Complications of HIV disease and therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 15:40-7. 2007
    ..As the field of clinical research in HIV continues to mature, we are repeatedly surprised by the findings from well-designed studies...
  47. ncbi request reprint Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome
    Susan E Cohn
    Infectious Diseases Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA
    Clin Infect Dis 34:1129-36. 2002
    ..Predictors of nonadherence are presented. These results underscore the clinical significance of adherence to HIV therapy and may be helpful in designing interventions to optimize the management of HIV by improving adherence...
  48. pmc Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination
    Arumugam Balamurugan
    Division of Infectious Diseases, 37 121 CHS, UCLA Medical Center, 10833 LeConte Ave, Los Angeles, CA 90095, USA
    J Virol 82:2784-91. 2008
    ....
  49. ncbi request reprint Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy
    Judith A Aberg
    Department of Medicine, Washington University School of Medicine, AIDS Clinical Trials Unit, St Louis, MO, 63108, USA
    Clin Infect Dis 35:E8-E13. 2002
    ..The low rate of these unusual MAC infections does not warrant continuation of primary or secondary prophylaxis after presumed immune reconstitution...
  50. ncbi request reprint A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
    Constance A Benson
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
    Clin Infect Dis 37:1234-43. 2003
    ..057). Subjects in the C+E+R group had improved survival, compared with the C+E group (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.23-0.83) and the C+R group (HR, 0.49; 95% CI, 0.26-0.92)...
  51. ncbi request reprint Getting smarter--the toxicity of undertreated HIV infection
    Judith S Currier
    N Engl J Med 355:2359-61. 2006
  52. ncbi request reprint Response to: 'carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients'
    Judith S Currier
    AIDS 20:311. 2006
  53. ncbi request reprint Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
    Morris Schambelan
    University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
    J Acquir Immune Defic Syndr 31:257-75. 2002
    ..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
  54. doi request reprint Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008
  55. ncbi request reprint Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women
    Judith S Currier
    Clin Infect Dis 45:261-2. 2007
  56. ncbi request reprint A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir
    Scott M Hammer
    Columbia University, New York, NY, USA
    Antivir Ther 8:507-18. 2003
  57. ncbi request reprint Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion
    Howard M Lederman
    Eudowood Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 188:1794-803. 2003
    ..009) and mumps skin test antigen (29% vs. 17%; P=.001). Although the subjects had only partial responses to immune function testing, the rate of opportunistic infections was very low, and none of the tests was predictive of risk...
  58. pmc State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary
    Steven K Grinspoon
    Circulation 118:198-210. 2008
  59. pmc Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s
    Francesca J Torriani
    Infection Prevention and Clinical Epidemiology Unit, University of California San Diego, 200 West Arbor Drive, MC 8951, San Diego, California 92103, USA
    J Am Coll Cardiol 52:569-76. 2008
    ..This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial...
  60. ncbi request reprint The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients
    Julie M Yasuda
    San Diego State University, San Diego, Calif, USA
    Antivir Ther 9:753-61. 2004
    ..The objective of this analysis was to assess the independent predictive value of protease inhibitor (PI) concentrations as a supplement to self-report as markers of medication adherence...
  61. ncbi request reprint Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil
    Beatriz Grinsztejn
    Evandro Chagas Clinical Research Institute FIOCRUZ, Av Brasil, 4365 Manguinhos, Rio de Janeiro, Brazil
    Int J STD AIDS 17:473-8. 2006
    ..Reproductive counselling should be a part of this approach...
  62. ncbi request reprint Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial
    Kathleen Mulligan
    Division of Endocrinology, San Francisco General Hospital, 1001 Potrero Avenue, Rm 3501K, San Francisco, CA 94110, USA
    Arch Intern Med 165:578-85. 2005
    ..Although studies have examined a variety of anabolic therapies in HIV-infected men, the safety and efficacy of such treatments in women have not been adequately studied...
  63. ncbi request reprint Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult
    Michael P Dube
    Indiana University, Indianapolis, USA
    Clin Infect Dis 37:613-27. 2003
  64. doi request reprint Risk of myocardial infarction and nucleoside analogues
    James H Stein
    Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53717, USA
    Lancet 371:1391-2. 2008
  65. ncbi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York 10016, USA
    Clin Infect Dis 39:609-29. 2004

Research Grants6

  1. UCLA AIDS Prevention and Treatment Clinical Trials Unit
    Judith Currier; Fiscal Year: 2007
    ..10. Stimulate community involvement and encourage participation of women and racial/ethnic minorities in ACTG, HPTN and VTN clinical trials at the UCLA-APT-CTU. ADMINISTRATIVE COMPONENT: ..
  2. Metabolic Complication of HIV Infection
    Judith Currier; Fiscal Year: 2007
    ..The strong support from my Division Chief and Department Chair to allow me to reduce my clinical and administrative responsibilities will greatly facilitate my success in achieving my goals. ..
  3. Prospective Evaluation of Antiviral Therapy and Cardiac Health
    James H Stein; Fiscal Year: 2010
    ..End of Abstract) ..